Unicycive Therapeutics (UNCY) Competitors $4.57 -0.04 (-0.76%) As of 03:03 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock UNCY vs. NMRA, SOPH, ABEO, ALLO, JBIO, FHTX, HUMA, VOR, ACB, and TNYAShould you be buying Unicycive Therapeutics stock or one of its competitors? The main competitors of Unicycive Therapeutics include Neumora Therapeutics (NMRA), SOPHiA GENETICS (SOPH), Abeona Therapeutics (ABEO), Allogene Therapeutics (ALLO), Jade Biosciences (JBIO), Foghorn Therapeutics (FHTX), Humacyte (HUMA), Vor Biopharma (VOR), Aurora Cannabis (ACB), and Tenaya Therapeutics (TNYA). These companies are all part of the "pharmaceutical products" industry. Unicycive Therapeutics vs. Its Competitors Neumora Therapeutics SOPHiA GENETICS Abeona Therapeutics Allogene Therapeutics Jade Biosciences Foghorn Therapeutics Humacyte Vor Biopharma Aurora Cannabis Tenaya Therapeutics Unicycive Therapeutics (NASDAQ:UNCY) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability. Is UNCY or NMRA more profitable? Neumora Therapeutics' return on equity of -98.95% beat Unicycive Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Unicycive TherapeuticsN/A -243.13% -119.46% Neumora Therapeutics N/A -98.95%-87.68% Do analysts prefer UNCY or NMRA? Unicycive Therapeutics currently has a consensus target price of $57.00, suggesting a potential upside of 1,148.63%. Neumora Therapeutics has a consensus target price of $7.14, suggesting a potential upside of 285.06%. Given Unicycive Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Unicycive Therapeutics is more favorable than Neumora Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Unicycive Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75Neumora Therapeutics 3 Sell rating(s) 4 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has higher earnings and valuation, UNCY or NMRA? Unicycive Therapeutics has higher revenue and earnings than Neumora Therapeutics. Neumora Therapeutics is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUnicycive Therapeutics$680K118.56-$36.73M-$4.12-1.11Neumora TherapeuticsN/AN/A-$243.79M-$1.57-1.18 Does the media favor UNCY or NMRA? In the previous week, Unicycive Therapeutics had 16 more articles in the media than Neumora Therapeutics. MarketBeat recorded 19 mentions for Unicycive Therapeutics and 3 mentions for Neumora Therapeutics. Neumora Therapeutics' average media sentiment score of 0.99 beat Unicycive Therapeutics' score of -0.02 indicating that Neumora Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Unicycive Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 15 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Neumora Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in UNCY or NMRA? 40.4% of Unicycive Therapeutics shares are held by institutional investors. Comparatively, 47.7% of Neumora Therapeutics shares are held by institutional investors. 10.7% of Unicycive Therapeutics shares are held by insiders. Comparatively, 26.8% of Neumora Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more risk and volatility, UNCY or NMRA? Unicycive Therapeutics has a beta of 1.86, meaning that its share price is 86% more volatile than the S&P 500. Comparatively, Neumora Therapeutics has a beta of 2.92, meaning that its share price is 192% more volatile than the S&P 500. SummaryNeumora Therapeutics beats Unicycive Therapeutics on 8 of the 15 factors compared between the two stocks. Get Unicycive Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for UNCY and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding UNCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UNCY vs. The Competition Export to ExcelMetricUnicycive TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$80.62M$2.69B$6.11B$10.54BDividend YieldN/A53.56%5.51%4.67%P/E Ratio-1.1123.8685.7226.88Price / Sales118.56607.52583.59184.34Price / CashN/A28.3526.3031.10Price / Book6.345.5513.246.71Net Income-$36.73M$32.78M$3.30B$276.44M7 Day Performance4.70%4.47%4.59%3.08%1 Month Performance4.70%10.05%8.31%10.20%1 Year Performance26.07%-1.60%87.88%40.77% Unicycive Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UNCYUnicycive Therapeutics2.3386 of 5 stars$4.57-0.8%$57.00+1,148.6%+23.1%$80.62M$680K-1.119NMRANeumora Therapeutics2.4475 of 5 stars$1.76+1.1%$7.14+305.8%-87.2%$281.79MN/A-1.12108SOPHSOPHiA GENETICS2.4886 of 5 stars$4.43+7.3%$8.00+80.6%+23.1%$279.10M$65.17M-10.07520Short Interest ↓High Trading VolumeABEOAbeona Therapeutics4.4218 of 5 stars$5.33-2.0%$19.50+265.9%-17.3%$278.95M$3.50M7.6190ALLOAllogene Therapeutics2.8419 of 5 stars$1.27+1.6%$8.44+564.9%-48.9%$277.35M$20K-1.14310Analyst UpgradeJBIOJade Biosciences2.0782 of 5 stars$8.62+1.7%$16.00+85.6%N/A$276.67MN/A-0.2820News CoverageFHTXFoghorn Therapeutics2.12 of 5 stars$5.01+3.1%$11.00+119.6%-42.1%$274.74M$22.60M-4.21120HUMAHumacyte2.8263 of 5 stars$1.73flat$9.29+436.7%-54.4%$273.98M$1.57M-3.84150News CoverageAnalyst ForecastOptions VolumeGap DownVORVor BiopharmaN/A$39.89+18.6%$113.83+185.4%N/A$273.41MN/A-24.18140Gap DownACBAurora Cannabis0.4625 of 5 stars$6.23+28.2%N/A+5.6%$273.24M$246.72M-32.791,130High Trading VolumeTNYATenaya Therapeutics3.1818 of 5 stars$1.58-4.8%$6.25+295.6%-2.8%$270.54MN/A-1.65110Gap Up Related Companies and Tools Related Companies Neumora Therapeutics Alternatives SOPHiA GENETICS Alternatives Abeona Therapeutics Alternatives Allogene Therapeutics Alternatives Jade Biosciences Alternatives Foghorn Therapeutics Alternatives Humacyte Alternatives Vor Biopharma Alternatives Aurora Cannabis Alternatives Tenaya Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:UNCY) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Unicycive Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Unicycive Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
